Latest Cutaneous leishmaniasis Stories
Unhealing Ulcers Afflict Millions, Including U.S.
A new way to test for the parasite which causes the fatal disease leishmaniasis could help control its spread to humans and stop dogs being needlessly killed in parts of South America.
The Amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease which in the Western world mainly affects dogs, but in developing countries affects over 12 million people, with more than 70,000 deaths per year.
Leishmaniasis is a vector borne disease caused by different Leishmania species with different clinical manifestations.
An international collaboration of researchers from the U.S. Army Medical Research and Materiel Command (USAMRMC), Tunisia and France has demonstrated a high cure rate and remarkably few side effects in treating patients with cutaneous leishmaniasis (CL) with an investigational antibiotic cream.
Belgian scientists of the Institute of Tropical Medicine (ITM) in Antwerp, Belgium made a breakthrough in bridging high tech molecular biology research on microbial pathogens and the needs of the poorest of the poor.
Genome sequencing alone provides researchers with only limited information on the organism works because it neither reveals how the system is regulated nor does it indicate the role of each specific DNA sequence or RNA transcript.